 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...187188189190191192193194195196197...235236» |
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Surgery: Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining (clinicaltrials.gov) - Sep 25, 2017
P=N/A, N=40, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed
- | New P2 trial, Metastases: FBI-TRAC: Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers (clinicaltrials.gov) - Sep 24, 2017
P2, N=32, Recruiting, Sponsor: King Faisal Specialist Hospital & Research Center
- | Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Sep 21, 2017
P2, N=6, Active, not recruiting, Sponsor: University of Miami
Recruiting --> Completed Recruiting --> Active, not recruiting | N=26 --> 6 | Trial primary completion date: Apr 2019 --> Mar 2017
- | Avastin (bevacizumab) / Roche
Enrollment open: IPOXA: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis (clinicaltrials.gov) - Sep 21, 2017
P1/2, N=47, Recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting | N=26 --> 6 | Trial primary completion date: Apr 2019 --> Mar 2017 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment (clinicaltrials.gov) - Sep 20, 2017
P4, N=50, Recruiting, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Apr 2018
- |||||||||| AryoTrust (trastuzumab biosimilar) / Inno Bio, AryoGen Pharmed, Stivant (bevacizumab biosimilar) / AryoGen Pharmed
New P3 trial, Head-to-Head: Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2017
P3, N=126, Active, not recruiting, Sponsor: AryoGen Pharmed Co.
- || Hepacid (pegargiminase) / Polaris Pharma
Trial primary completion date, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 19, 2017
P1, N=148, Recruiting, Sponsor: Polaris Group
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Aug 2017 --> Aug 2019
- | Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment change, Trial termination, Trial primary completion date: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2017
P2, N=1, Terminated, Sponsor: City of Hope Medical Center
Trial primary completion date: Aug 2017 --> Aug 2019 N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Sep 2017; Poor Accrual
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) - Sep 18, 2017
P2, N=56, Active, not recruiting, Sponsor: John Hays
N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Sep 2017; Poor Accrual Trial primary completion date: Sep 2017 --> Dec 2017
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, PD(L)-1 Biomarker, Metastases: MEDITREME: Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (clinicaltrials.gov) - Sep 18, 2017
P1/2, N=48, Recruiting, Sponsor: Centre Georges Francois Leclerc
Trial primary completion date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New trial, Metastases: Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 17, 2017
P=N/A, N=1800, Recruiting, Sponsor: Joong Bae Ahn
- | 5-fluorouracil / Generic mfg.
Enrollment closed, Enrollment change, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - Sep 15, 2017
P1, N=14, Active, not recruiting, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=20 --> 14
- |||| veliparib (ABT-888) / AbbVie
Trial completion, Metastases: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 15, 2017
P2, N=131, Completed, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=20 --> 14 Active, not recruiting --> Completed
- | Tecentriq (atezolizumab) / Roche
Enrollment open, Mismatch repair, Tumor mutational burden, PD(L)-1 Biomarker: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - Sep 15, 2017
P3, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: TRIBE2: Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (clinicaltrials.gov) - Sep 14, 2017
P3, N=654, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> May 2017
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Sep 13, 2017
P2, N=39, Not yet recruiting, Sponsor: Al B. Benson, III, MD
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Sep 13, 2017
P1, N=32, Active, not recruiting, Sponsor: Oncolytics Biotech
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> May 2017 Trial primary completion date: Oct 2017 --> Feb 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Sep 13, 2017
P2, N=25, Recruiting, Sponsor: howard safran
Trial primary completion date: Oct 2017 --> Feb 2018 Trial primary completion date: Mar 2017 --> Mar 2018
- ||||| Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
New P1/2 trial, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Sep 13, 2017
P1/2, N=357, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial suspension: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Sep 12, 2017
P3, N=5437, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Suspended
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P1 trial, Combination therapy: A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (clinicaltrials.gov) - Sep 12, 2017
P1, N=25, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | New P2 trial, Metastases: NEOLAR: NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Sep 11, 2017
P2, N=124, Recruiting, Sponsor: Zealand University Hospital
- |||| Vectibix (panitumumab) / Amgen
Trial completion: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Sep 11, 2017
P2, N=164, Completed, Sponsor: Takeda
Recruiting --> Suspended Active, not recruiting --> Completed
- | sapitinib (AZD8931) / AstraZeneca
Enrollment closed, Enrollment change, Combination therapy: PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) - Sep 11, 2017
P2, N=24, Active, not recruiting, Sponsor: University College, London
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 24
- | leucovorin calcium / Generic mfg.
Trial initiation date, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Sep 11, 2017
P3, N=160, Not yet recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | N=60 --> 24 Initiation date: Nov 2016 --> Nov 2017 | Trial primary completion date: Jan 2021 --> Jan 2022
- | Imkeldi (imatinib) / Shorla Oncology
IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 11, 2017
P3, N=700, Recruiting, Sponsor: Children's Oncology Group
Initiation date: Nov 2016 --> Nov 2017 | Trial primary completion date: Jan 2021 --> Jan 2022 Trial primary completion date: Dec 2025 --> Jun 2026
- Trial primary completion date: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 7, 2017
P2, N=39, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2025 --> Jun 2026 Trial primary completion date: Aug 2017 --> Aug 2018
- Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: HCRN GI14-186: Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2017
P2, N=30, Active, not recruiting, Sponsor: Safi Shahda, M.D.
Trial primary completion date: Aug 2017 --> Aug 2018 Trial primary completion date: Aug 2017 --> Apr 2018
- ||||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
Enrollment closed, Metastases: INVICTAN (clinicaltrials.gov) - Sep 6, 2017
P3, N=120, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Aug 2017 --> Apr 2018 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial suspension, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 5, 2017
P1b/2, N=68, Suspended, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Suspended
- | IMM-101 / Immodulon
Trial termination, Trial primary completion date: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) - Sep 5, 2017
P1/2, N=300, Terminated, Sponsor: Immodulon Therapeutics Ltd
Recruiting --> Suspended Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> Aug 2017; Commercial reasons
- | AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) (clinicaltrials.gov) - Sep 5, 2017
P2, N=80, Not yet recruiting, Sponsor: Shenzhen People's Hospital
- | Enrollment change, Trial termination, Trial primary completion date, Metastases: mEGA: Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (clinicaltrials.gov) - Sep 1, 2017
P=N/A, N=13, Terminated, Sponsor: Georgetown University
Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> Aug 2017; Commercial reasons N=20 --> 13 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2016; Issues with recruitment.
- ||| Biomarker, Enrollment change, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 1, 2017
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
N=20 --> 13 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2016; Issues with recruitment. N=610 --> 1400 | Trial primary completion date: Feb 2019 --> Oct 2020
- | Imkeldi (imatinib) / Shorla Oncology
IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 31, 2017
P3, N=700, Recruiting, Sponsor: Children's Oncology Group
N=610 --> 1400 | Trial primary completion date: Feb 2019 --> Oct 2020 Not yet recruiting --> Recruiting
- | Trial completion, Metastases: Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 30, 2017
P2, N=75, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || BNT321 / BioNTech
Trial primary completion date, Monotherapy: MV-0715-CP-001.01: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies (clinicaltrials.gov) - Aug 30, 2017
P1, N=68, Recruiting, Sponsor: MabVax Therapeutics, Inc.
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Dec 2017
- | Avastin (bevacizumab) / Roche
Trial termination, Trial primary completion date: Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis (clinicaltrials.gov) - Aug 29, 2017
P2, N=50, Terminated, Sponsor: University of California, San Diego
Trial primary completion date: Jun 2017 --> Dec 2017 Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Feb 2017; unable to accrue
- | Enrollment open, Surgery: A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer (clinicaltrials.gov) - Aug 29, 2017
P2, N=20, Recruiting, Sponsor: Petr Kavan
Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Feb 2017; unable to accrue Not yet recruiting --> Recruiting
- |||| E7820 / Eisai
Trial completion, Trial primary completion date, Metastases: Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer (clinicaltrials.gov) - Aug 28, 2017
P1/2, N=82, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2015
- |||| Enrollment open, Trial initiation date: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Aug 25, 2017
P1/2, N=80, Recruiting, Sponsor: NantCell, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2015 Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Aug 2017
- ||| Jemperli (dostarlimab-gxly) / GSK
New P1 trial, Combination therapy, Metastases: CITRINO: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 23, 2017
P1, N=260, Recruiting, Sponsor: Tesaro, Inc.
- | pyrimethamine / Generic mfg.
New P1 trial: Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - Aug 22, 2017
P1, N=12, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Trial primary completion date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=42, Active, not recruiting, Sponsor: Philip Philip
Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Aug 2017 Trial primary completion date: Apr 2017 --> Nov 2017
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Trial completion, Enrollment change: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Aug 22, 2017
P1/2, N=8, Completed, Sponsor: Isofol Medical AB
Trial primary completion date: Apr 2017 --> Nov 2017 Recruiting --> Completed | N=12 --> 8
- | Trial primary completion date, Metastases: GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. (clinicaltrials.gov) - Aug 21, 2017
P1/2, N=60, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Recruiting --> Completed | N=12 --> 8 Trial primary completion date: Mar 2015 --> Mar 2018
- | Trial primary completion date, Surgery, Metastases: CAOAROAIO-12: Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 21, 2017
P2, N=304, Recruiting, Sponsor: Prof. Dr. med. Claus R
Trial primary completion date: Mar 2015 --> Mar 2018 Trial primary completion date: May 2017 --> Mar 2018
- | oxaliplatin / Generic mfg.
New P1/2 trial: Lidocaine for Oxaliplatin-induced Neuropathy (clinicaltrials.gov) - Aug 18, 2017
P1/2, N=38, Recruiting, Sponsor: Washington University School of Medicine
- ||| palupiprant (AN0025) / Eisai, Adlai Nortye
Enrollment open, Trial primary completion date, Combination therapy: PRAER 1: Preoperative Radiotherapy and E7046 in Rectum Cancer (clinicaltrials.gov) - Aug 15, 2017
P1b, N=68, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: May 2017 --> Mar 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2019 --> Apr 2018
- | Avastin (bevacizumab) / Roche
Trial primary completion date: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Aug 11, 2017
P1, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2019 --> Apr 2018 Trial primary completion date: Sep 2017 --> Sep 2018